GLP-1 Pipeline and Policy Shifts

Medicare coverage for GLP-1s begins July 2026 ($50/month). Oral orforglipron (Foundayo) approved April 2026, showing 50% greater weight loss than oral semaglutide. Retatrutide BLA expected Q1 2027 with 28-30% weight loss. A recent clinical guideline adds NNT/NNH precision: semaglutide NNT 2 for 10% loss, phentermine/topiramate 8.5% loss. Today's reading 'Beyond the Scale' reinforces the paradigm shift to long-term metabolic care. These developments are reshaping access and options for midlife weight loss.